China has gradually entered an aging society, and with the continuous increase in the elderly population, it is expected that by 2025, the population aged 65 and above will reach about 250 million people, with a compound annual growth rate of 5.4% from 2020 to 2025. By 2030, it is expected to reach 320 million. The weakened immune and metabolic systems of the aging population often lead to higher dependence and consumption of drugs. The increasingly severe aging population structure in China will be one of the important driving factors for the rapid growth of the pharmaceutical market. On the other hand, the National Medical Products Administration will actively implement the decision-making arrangements of the Central Committee of the Communist Party of China and the State Council, fully cooperate with the continuous deepening of healthcare reform, continuously promote the reform of drug and medical device review and approval systems, take effective measures to better meet the public's medication needs, and effectively ensure public medication safety. The innovative drug market in China has entered a period of vigorous development.
This study focuses on the Chinese hepatocellular carcinoma market, exploring and analyzing market opportunities, future business space, market drivers, and trends for innovative drugs for hepatocellular carcinoma. In addition, the latest newly launched traditional Chinese medicine (TCM) innovative drugs for hepatocellular carcinoma are also included as one of the research topics. Based on this, Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') has released the 'Research Report on the Market for Innovative Drugs for Chinese Hepatocellular Carcinoma'.
The attachment is a condensed report. If you have further research needs on this topic or require the full version of the research report, please contact us at any time:
Mr. Lu from Frost & Sullivan
Tel: (+86)151-2106-7206
E-mail: gabriel.lu@frostchina.com
